LEGN250117P65000
- 0.00
- 0.000.00%
Legend Biotech Newsroom
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Legend Biotech Analyst Ratings
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $84
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Promising Growth Trajectory and Market Expansion Justify Buy Rating for Legend Biotech
RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating
Legend Biotech Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and NewAmsterdam Pharma Company (NAMS)
Piper Sandler Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $78
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $65 to $91
Optimistic Buy Rating for Legend Biotech Driven by Carvykti's Success and Growth Potential
William Blair Sticks to Its Hold Rating for Legend Biotech (LEGN)
Legend Biotech Analyst Ratings
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $86
Cantor Fitzgerald Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $83
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)